News
Academy
Publications
All PublicationsE-Books
Media
Editorial PodcastsEditorial VideosPeer ExchangePractice AcademySponsored PodcastsSponsored Videos
More
Conferences
Conference CoverageConference Listing
Columns
All ColumnsA Closing ThoughtClinical Trial InsightsView from BrusselsView from Washington
Resources
AdvertiseBlogsEventsFront & CenterPartner PerspectivesWhite Papers
Webcasts

Subscribe

  • News
  • Academy
  • Publications
  • Media
  • Conferences
  • Columns
  • Resources
  • Webcasts
  • Subscribe
  • Clinical Operations & Strategy
    • Decentralized Clinical Trials
    • Trial Design
    • Investigative Sites
    • CRO/Sponsor
    • Risk-Based Monitoring
    • Protocol Design
    • Clinical Trial Supply Chain
    • Study Start-Up
    • Early Phase Development
  • DEI
    • Industry Initiatives
    • Diversity Action Plans
    • Recruitment
  • Data Management
    • Analytics
    • Electronic Data Capture
    • Real World Evidence
    • Metrics & Benchmarks
  • Patient Participation
    • Integrated Research
    • CRAACO
    • Enrollment
  • Regulatory
    • Institutional Review Board & Ethics Committee
    • FDA
    • EMA
  • Technology
    • Artificial Intelligence/Machine Learning
    • eClinical
    • mHealth
Spotlight -
CNS Drug Development Resources|
Conference Coverage|
Peer Exchange|
DE&I|
Editorial Videos
Advertisement
|Articles|September 29, 2015

ACRES, Clinical Trials Ontario Form Partnership

Advertisement

See this news from Pharmaceutical Executive on the latest out of ACRES.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Advertisement

Related Content

Advertisement
© Creative Cat Studio - © Creative Cat Studio - stock.adobe.com

Praxis Reports Positive Phase III Results for Ulixacaltamide in Essential Tremor

ByAndy Studna, Senior Editor
October 16th 2025
© Kaikoro - © Kaikoro - stock.adobe.com

Setting the Limits of Autonomy with Autonomous Agents for Clinical Research

ByAndrew Mackinnon,Alison Holland
October 16th 2025

Retention by Design: Operationalizing Patient-Centric Trials Without Increasing Site Burden

ByKees Van Ooik ,Mike Hutton, PhD
October 16th 2025

Streamlining Trial Design to Accelerate Data Delivery and Investor Confidence

ByBen Edwards,Andy Studna, Senior Editor
October 16th 2025
Credit: New Africa | stock.adobe.com

Eli Lilly’s Orforglipron Shows Superior Efficacy Across Multiple Phase III Trials in Type 2 Diabetes

ByAndy Studna, Senior Editor
October 15th 2025
Advertisement
Advertisement

Trending on Applied Clinical Trials Online

1

Future-Proofing Clinical Trial Supply Chains Against Tariff Risks

2

Eli Lilly’s Orforglipron Shows Superior Efficacy Across Multiple Phase III Trials in Type 2 Diabetes

3

Reframing the IND: From Tactical Requirement to Strategic Opportunity

4

Streamlining Trial Design to Accelerate Data Delivery and Investor Confidence

5

Labels That Withstand Liquid Nitrogen

  • About
  • Advertise
  • Contact Us
  • Editorial Contacts
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Applied Clinical Trials
  • BioPharm International
  • Cannabis Science and Technology
  • Chromatography Online
  • Nutritional Outlook
  • Pharmaceutical Commerce
  • Pharmaceutical Executive
  • Pharm Tech
  • Spectroscopy Online
  • Turbo Machinery Magazine
IS1
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us